Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 3 | -$0.61 | -$0.56 | -$0.59 |
Q2 2025 | 2 | -$0.91 | -$0.24 | -$0.60 |
Q3 2025 | 2 | -$0.97 | -$0.26 | -$0.64 |
Q4 2025 | 2 | -$0.88 | -$0.23 | -$0.58 |
Stoke Therapeutics, Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-0.47 earnings per share for the quarter, topping analysts' consensus estimates of $-0.52 by $0.05. The company had revenue of 4.89 M for the quarter and had revenue of 8.78 M for the year. Stoke Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.38 diluted earnings per share) and currently has a price-to-earnings ratio of -5.72. Stoke Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 24th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/05/2024 | Q3 2024 | -$0.52 | -$0.47 | 0.05 | $3.83 M | $4.89 M |
08/07/2024 | Q2 2024 | -$0.57 | -$0.46 | 0.11 | $3.70 M | $4.83 M |
05/06/2024 | Q1 2024 | -$0.60 | -$0.57 | 0.03 | $4.22 M | |
03/25/2024 | Q4 2023 | -$0.60 | $2.80 M | |||
11/07/2023 | Q3 2023 | -$0.65 | -$0.55 | 0.1 | $3.64 M | $3.31 M |
08/07/2023 | Q2 2023 | -$0.65 | -$0.69 | -0.04 | $3.44 M | $-2,481,000 |
05/04/2023 | Q1 2023 | -$0.70 | -$0.43 | 0.27 | $5.15 M | |
03/06/2023 | Q4 2022 | -$0.72 | -$0.56 | 0.16 | $3.27 M | |
11/14/2022 | Q3 2022 | -$0.69 | -$0.61 | 0.08 | $2.72 M | $2.91 M |
08/08/2022 | Q2 2022 | -$0.70 | -$0.59 | 0.11 | $2.64 M | $3.23 M |
05/10/2022 | Q1 2022 | $0.61 | -$0.65 | -1.26 | $3.00 M | |
03/10/2022 | Q4 2021 | -$0.62 | -$0.66 | -0.04 | $0 | |
11/08/2021 | Q3 2021 | -$0.58 | -$0.61 | -0.03 | $0 | |
08/10/2021 | Q2 2021 | -$0.49 | -$0.60 | -0.11 | $0 | |
05/10/2021 | Q1 2021 | -$0.44 | -$0.46 | -0.02 | $0 | |
03/09/2021 | Q4 2020 | -$0.43 | -$0.44 | -0.01 | $0 | |
11/12/2020 | Q3 2020 | -$0.42 | -$0.41 | 0.01 | $0 | |
08/10/2020 | Q2 2020 | -$0.36 | -$0.39 | -0.03 | $0 | |
05/15/2020 | Q1 2020 | -$0.37 | -$0.34 | 0.03 | $0 | |
03/23/2020 | Q4 2019 | -$0.31 | $0 |
Stoke Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 24th, 2025 based off last year's report dates.
In the previous quarter, Stoke Therapeutics, Inc. (:STOK) reported $-0.47 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.52 by $0.05.
The conference call for Stoke Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Stoke Therapeutics, Inc.'s latest earnings report can be read online.
Stoke Therapeutics, Inc. (:STOK) has a recorded annual revenue of $8.78 M.
Stoke Therapeutics, Inc. (:STOK) has a recorded net income of $8.78 M. Stoke Therapeutics, Inc. has generated $-2.38 earnings per share over the last four quarters.
Stoke Therapeutics, Inc. (:STOK) has a price-to-earnings ratio of -5.72 and price/earnings-to-growth ratio is -1.56.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED